Busan, South Korea

Nam Hee Lee



 

Average Co-Inventor Count = 3.7

ph-index = 1


Company Filing History:


Years Active: 2019-2020

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Nam Hee Lee: Innovator in Oncolytic Virus Research

Introduction

Nam Hee Lee is a prominent inventor based in Busan, South Korea. He has made significant contributions to the field of cancer treatment through his innovative research on oncolytic viruses. With a total of 2 patents, his work focuses on developing advanced therapeutic methods for combating cancer.

Latest Patents

Nam Hee Lee's latest patents include groundbreaking inventions that enhance cancer treatment. One of his patents is titled "Modified oncolytic vaccinia viruses expressing a cytokine and a carboxylesterase and methods of use thereof." This patent pertains to compositions and combinations for simultaneous, separate, or sequential use, which includes an oncolytic vaccinia virus that expresses a cytokine and a carboxylesterase enzyme, along with a cancer co-drug for effective cancer treatment. Another significant patent is "Compositions and methods for viral embolization," which relates to oncolytic viruses used in transcatheter arterial viroembolization methods. This patent provides compositions with oncolytic viruses combined with biocompatible microparticles or hydrophilic polymer gel agents suitable for active embolization.

Career Highlights

Nam Hee Lee is associated with Sillajen, Inc., a company dedicated to advancing cancer therapies through innovative research. His work at Sillajen has positioned him as a key figure in the development of oncolytic virus therapies.

Collaborations

Nam Hee Lee collaborates with notable colleagues, including Tae Ho Hwang and Euna Cho. Their combined expertise contributes to the advancement of research in the field of oncolytic viruses.

Conclusion

Nam Hee Lee's innovative work in the field of oncolytic viruses represents a significant advancement in cancer treatment. His patents and collaborations highlight his commitment to improving therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…